
Oncopeptides AB (publ)
SSE:ONCO.ST
7.26 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Oncopeptides AB (publ) |
Symbool | ONCO.ST |
Munteenheid | SEK |
Prijs | 7.264 |
Beurswaarde | 656,953,465 |
Dividendpercentage | 0% |
52-weken bereik | 6.21 - 12.4 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jakob Lindberg Med. Lic |
Website | https://www.oncopeptides.com/sv |
An error occurred while fetching data.
Over Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)